Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AML

Blood (2022) 139 (8): 1208–1221.

https://doi.org/10.1182/blood.2021011354

Published: 2022

Includes: Supplemental data

Journal Articles

Framework to Identify and Prioritize Candidate Inherited Myeloid Malignancy Germline Variants Leveraging the BEAT AML Cohort

Daniel Bottomly, Nicola Long, Fei Yang, MD, Tiffany Lee, MD, Uma Borate, MD, Beth Wilmot, PhD, Adam S DuVall, MD, Andrea Monteblanco, BS, Karina Thiel-Klare, Gabby Dewson, BA, Richard D. Press, MD PhD, Cristina E. Tognon, Brian J. Druker, Jeffrey W. Tyner, Shannon K. McWeeney, PhD, Anupriya Agarwal, PhD

Blood (2019) 134 (Supplement_1): 1407.

https://doi.org/10.1182/blood-2019-132224

Published: 2019

Journal Articles

Genomic landscape of neutrophilic leukemias of ambiguous diagnosis

Blood (2019) 134 (11): 867–879.

https://doi.org/10.1182/blood.2019000611

Published: 2019

Includes: Supplemental data

Journal Articles

Significant In Vivo Sensitivity to Aurora Kinase Inhibition in TCF3-Hlf rearranged Acute Lymphoblastic Leukemia

Bill H. Chang, MD PhD, Jessica Leonard, MD, Joelle Wolf, Michelle Degnin, BS, Kyle Lenz, MD, Beth Wilmot, PhD, Charles G. Mullighan, MBBS, MD, Mignon L. Loh, MD, Stephen P. Hunger, MD, Jeffrey W. Tyner, PhD, Brian J. Druker, MD

Blood (2018) 132 (Supplement 1): 4026.

https://doi.org/10.1182/blood-2018-99-115706

Published: 2018

Journal Articles

Biomarkers Predicting Venetoclax Sensitivity and Strategies for Venetoclax Combination Treatment

Haijiao Zhang, Beth Wilmot, PhD, Daniel Bottomly, Stephen E Kurtz, PhD, Christopher A. Eide, Alisa Damnernsawad, Kyle Romine, Shyam Patel, Brian J. Druker, MD, Schannon K Mcweeney, Ravi Majeti, MD PhD, Jeffrey W. Tyner, PhD

Blood (2018) 132 (Supplement 1): 175.

https://doi.org/10.1182/blood-2018-175

Published: 2018

Journal Articles

Identification of Effective Combinations of Targeted Drugs for DNMT3A and NPM1 Mutated Acute Myeloid Leukemia

Stephen E Kurtz, PhD, Christopher A. Eide, Andy Kaempf, Samantha L Savage, Anna M. Reister Schultz, Beth Wilmot, PhD, Shannon Mcweeney, PhD, Motomi Mori, PhD, Elie Traer, MD PhD, Brian J. Druker, MD, Jeffrey W. Tyner, PhD

Blood (2017) 130 (Supplement 1): 2068.

https://doi.org/10.1182/blood.V130.Suppl_1.2068.2068

Published: 2017

Journal Articles

Differential Ex Vivo Sensitivity Patterns to Small-Molecule Inhibitors and Combination Therapies Among Acute Myeloid Leukemia Patients Harboring Both FLT3 and NPM1 Mutations

Christopher A. Eide, Stephen E Kurtz, PhD, Andy Kaempf, Andrew Park, Angela Rofelty, Beth Wilmot, PhD, Daniel Bottomly, Shannon K. McWeeney, PhD, Cristina E. Tognon, PhD, Motomi Mori, PhD, Jeffrey W. Tyner, PhD, Brian J. Druker, MD

Blood (2017) 130 (Supplement 1): 1422.

https://doi.org/10.1182/blood.V130.Suppl_1.1422.1422

Published: 2017

Journal Articles

Therapeutically Targetable Activating c-ABL1 Mutations in Philadelphia Chromosome-Negative Leukemias

Samantha L Savage, Julia E. Maxson, PhD, Christopher A. Eide, Chelsea Jenkins, B.S., Melissa L Abel, Anna M. Reister Schultz, Daniel Bottomly, Beth Wilmot, PhD, Shannon Mcweeney, PhD, Cristina E. Tognon, PhD, Jeffrey W. Tyner, PhD, Brian J. Druker, MD

Blood (2017) 130 (Supplement 1): 3930.

https://doi.org/10.1182/blood.V130.Suppl_1.3930.3930

Published: 2017

Journal Articles

CG '806, a First-in-Class Pan-FLT3/BTK Inhibitor, Exhibits Potent Growth Inhibition As a Single Agent and in Combination with a BET Bromodomain Inhibitor or a Bcl2 Inhibitor on Primary AML and CLL Patient Samples

Stephen E Kurtz, PhD, Beth Wilmot, PhD, Shannon Mcweeney, PhD, Andrea Local, PhD, Hongying Zhang, MD, Stephen Howell, MD, William Rice, PhD, Brian J. Druker, MD, Jeffrey W. Tyner, PhD

Blood (2017) 130 (Supplement 1): 4626.

https://doi.org/10.1182/blood.V130.Suppl_1.4626.4626

Published: 2017

Journal Articles

Coexisting Oncogenic Signaling Pathway Mutations in Cnl/Acml/CMML/MPN-U

Haijiao Zhang, Daniel Bottomly, Libbey K. White, Beth Wilmot, PhD, Shannon Mcweeney, PhD, Jeffrey W. Tyner, PhD

Blood (2017) 130 (Supplement 1): 4213.

https://doi.org/10.1182/blood.V130.Suppl_1.4213.4213

Published: 2017

Journal Articles

High-Throughput Validation of Mutations Identified in Primary Leukemia Cells

Michelle Degnin, BASc, Cristina E. Tognon, Christopher A. Eide, Beth Wilmot, Shannon K. McWeeney, Daniel Bottomly, Rebecca Smith, BASc, Brian J. Druker

Blood (2016) 128 (22): 4725.

https://doi.org/10.1182/blood.V128.22.4725.4725

Published: 2016

Journal Articles

Recurrent Pathogenic Cyclin D2 Mutations in Myeloid Malignancies

Vishesh Khanna, BS, Christopher A. Eide, Cristina E. Tognon, Julia E. Maxson, PhD, Beth Wilmot, Daniel Bottomly, Shannon K. McWeeney, Brian J. Druker, MD, Jeffrey W. Tyner

Blood (2016) 128 (22): 2734.

https://doi.org/10.1182/blood.V128.22.2734.2734

Published: 2016

Journal Articles

Definition of the Minimal Truncated Elements Necessary for CSF3R Leukemogenic Potential

Haijiao Zhang, MD, Anna Reister Schultz, B.S., Samuel B Luty, BS, Sophie Means, B.S., Larry David, PhD, John Klimek, B.S., Daniel Bottomly, Beth Wilmot, Shannon McWeeney, PhD, Yulong Su, B.S., Jeffrey W. Tyner

Blood (2016) 128 (22): 2735.

https://doi.org/10.1182/blood.V128.22.2735.2735

Published: 2016

Journal Articles

Transforming Growth Factor- β1 Signaling in Vascular Endothelial Cells Inhibits Hematopoietic Stem Cell Regeneration

Derek Zachman, MS, Devorah C Goldman, PhD, Chandan Guha, MD PhD, Beth Wilmot, William H. Fleming, MD PhD

Blood (2016) 128 (22): 1493.

https://doi.org/10.1182/blood.V128.22.1493.1493

Published: 2016

Journal Articles

Characterization of the Genomic Landscape of BCR-ABL1 Kinase-Independent Mechanisms of Resistance to ABL1 Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Blood (2016) 128 (22): 1119.

https://doi.org/10.1182/blood.V128.22.1119.1119

Published: 2016

Journal Articles

Exome Sequencing Informs Mechanisms of Clinical Resistance to the FLT3-D835 Inhibitor Crenolanib

Haijiao Zhang, MD, Kevin Matthew Watanabe-Smith, BS, Daniel Bottomly, MS, Beth Wilmot, PhD, Shannon K. McWeeney, PhD, Hagop M. Kantarjian, MD, Judy Ho, Jeremy Davis, Blake Pond, MS, Gautam Borthakur, MD, Abhijit Ramachandran, MS, Jorge E. Cortes, Robert Collins, MD, Jeffrey W. Tyner, PhD

Blood (2015) 126 (23): 2468.

https://doi.org/10.1182/blood.V126.23.2468.2468

Published: 2015

Journal Articles

Broad Activity of Apto-253 in AML and Other Hematologic Malignancies Correlates with KLF4 Expression Level

Stephen E. Kurtz, PhD, Daniel Bottomly, MS, Beth Wilmot, PhD, Shannon K. McWeeney, PhD, William Rice, PhD, Stephen B Howell, MD, Avanish Vellanki, Brian J. Druker, MD, Jeffrey W. Tyner, PhD

Blood (2015) 126 (23): 1358.

https://doi.org/10.1182/blood.V126.23.1358.1358

Published: 2015

Journal Articles

Activating Mutations of Insulin Receptor Substrate 2 (IRS2) in Patients with Tyrosine Kinase Inhibitor-Refractory Chronic Myeloid Leukemia

Samantha L Savage, Christopher A. Eide, Kyle F Concannon, Daniel Bottomly, MS, Beth Wilmot, PhD, Shannon K. McWeeney, PhD, Julia Elizabeth Maxson, PhD, Jeffrey W. Tyner, PhD, Cristina E. Tognon, PhD, Brian J. Druker, MD

Blood (2015) 126 (23): 2461.

https://doi.org/10.1182/blood.V126.23.2461.2461

Published: 2015

Journal Articles

Activating Mutations Observed in De Novo Acute Myeloid Leukemia Are Also Present in a Subset of Philadelphia Chromosome (Ph)-Positive Leukemia Patients with BCR-ABL1-Independent Resistance to ABL1 Kinase Inhibitors

Christopher A. Eide, Samantha L. Savage, Anupriya Agarwal, Daniel Bottomly, Beth Wilmot, Shannon K. McWeeney, Stephen E. Kurtz, Thomas O'Hare, Michael W. Deininger, Marc M. Loriaux, Cristina E. Tognon, Jeffrey W. Tyner, Brian J. Druker

Blood (2014) 124 (21): 4514.

https://doi.org/10.1182/blood.V124.21.4514.4514

Published: 2014

Journal Articles

Philadelphia Chromosome (Ph)-Positive Leukemia Patients Who Fail ABL1 Tyrosine Kinase Inhibitors Without BCR-ABL1 Kinase Domain Point Mutations Demonstrate Sensitivity To PI3-K/AKT Inhibitors

Christopher A. Eide, Samantha L. Savage, Jade Bryant, Anupriya Agarwal, Daniel Bottomly, Beth Wilmot, Shannon K. McWeeney, Thomas O'Hare, Michael W. Deininger, Marc M. Loriaux, Cristina E. Tognon, Jeffrey W. Tyner, Brian J. Druker

Blood (2013) 122 (21): 3994.

https://doi.org/10.1182/blood.V122.21.3994.3994

Published: 2013

NARROW

Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AML

Framework to Identify and Prioritize Candidate Inherited Myeloid Malignancy Germline Variants Leveraging the BEAT AML Cohort

Genomic landscape of neutrophilic leukemias of ambiguous diagnosis

Significant In Vivo Sensitivity to Aurora Kinase Inhibition in TCF3-Hlf rearranged Acute Lymphoblastic Leukemia

Biomarkers Predicting Venetoclax Sensitivity and Strategies for Venetoclax Combination Treatment

Identification of Effective Combinations of Targeted Drugs for DNMT3A and NPM1 Mutated Acute Myeloid Leukemia

Differential Ex Vivo Sensitivity Patterns to Small-Molecule Inhibitors and Combination Therapies Among Acute Myeloid Leukemia Patients Harboring Both FLT3 and NPM1 Mutations

Therapeutically Targetable Activating c-ABL1 Mutations in Philadelphia Chromosome-Negative Leukemias

CG '806, a First-in-Class Pan-FLT3/BTK Inhibitor, Exhibits Potent Growth Inhibition As a Single Agent and in Combination with a BET Bromodomain Inhibitor or a Bcl2 Inhibitor on Primary AML and CLL Patient Samples

Coexisting Oncogenic Signaling Pathway Mutations in Cnl/Acml/CMML/MPN-U

High-Throughput Validation of Mutations Identified in Primary Leukemia Cells

Recurrent Pathogenic Cyclin D2 Mutations in Myeloid Malignancies

Definition of the Minimal Truncated Elements Necessary for CSF3R Leukemogenic Potential

Transforming Growth Factor- β1 Signaling in Vascular Endothelial Cells Inhibits Hematopoietic Stem Cell Regeneration

Characterization of the Genomic Landscape of BCR-ABL1 Kinase-Independent Mechanisms of Resistance to ABL1 Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Exome Sequencing Informs Mechanisms of Clinical Resistance to the FLT3-D835 Inhibitor Crenolanib

Broad Activity of Apto-253 in AML and Other Hematologic Malignancies Correlates with KLF4 Expression Level

Activating Mutations of Insulin Receptor Substrate 2 (IRS2) in Patients with Tyrosine Kinase Inhibitor-Refractory Chronic Myeloid Leukemia

Activating Mutations Observed in De Novo Acute Myeloid Leukemia Are Also Present in a Subset of Philadelphia Chromosome (Ph)-Positive Leukemia Patients with BCR-ABL1-Independent Resistance to ABL1 Kinase Inhibitors

Philadelphia Chromosome (Ph)-Positive Leukemia Patients Who Fail ABL1 Tyrosine Kinase Inhibitors Without BCR-ABL1 Kinase Domain Point Mutations Demonstrate Sensitivity To PI3-K/AKT Inhibitors

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only